Justia Patents Opinion Summaries

Wake Forest is the owner of asserted patents, and KCI are the exclusive licensees of the patents, which claim methods and apparatuses for treating difficult-to-heal wounds by applying suction or negative pressure. In response to S&N’s 2008 announcement that it was launching a new foam-based negative pressure wound treatment product, Wake Forest and KCI asserted that S&N infringes two apparatus claims of the patent and induces infringement of four method claims. Rejecting the jury’s findings of non-obviousness, the district court found obviousness, based on prior art, and rejected infringement claims. The Federal Circuit reversed and remanded. The objective evidence strongly supported the jury’s findings under the first three Graham factors and cut against the view that the claimed inventions were an obvious combination of known elements from the prior art. View "Kinetic Concepts, Inc. v. Smith & Nephew, Inc." on Justia Law

Apotex submitted an Abbreviated New Drug Application (ANDA) to the FDA seeking approval to market a generic version of the anti-allergy eye drop Patanol. Alcon, which markets Patanol, sued Apotex for patent infringement under 35 U.S.C. 271(e)(2)(A). Alcon asserted claims 1-8 of the patent, which is listed in the Approved Drug Products with Therapeutic Equivalence Evaluations (Orange Book) entry for Patanol. The district court held that claims would not have been obvious over the prior art and were not invalid. The Federal Circuit affirmed in part. Objective evidence indicated that claims 4 and 8 would not have been obvious. Patanol’s achieving nearly 70% market share within two years of its launch, demonstrates that “the commercial success was caused by the merits of the invention as distinct from the prior art.” The remaining claims were, however, obvious. A person of ordinary skill in the art at the time of invention would have been motivated to use olopatadine to treat human eye allergies as claimed for its established antihistaminic efficacy. View "Alcon Research, Ltd. v. Apotex, Inc." on Justia Law

Allcare owns a patent directed to “managed health care systems” used to interconnect and integrate physicians, medical care facilities, patients, insurance companies, and financial institutions, particularly with respect to utilization review, the process of determining whether a health insurer should approve a particular treatment for a patient. In general, the patent’s claims cover a method of determining whether utilization review is necessary in a particular instance, and whether a recommended treatment is appropriate. If utilization review is required, the method prevents authorization and payment until the appropriateness of the treatment has been determined and the treatment has been approved. The district court held that the patent was not infringed by Highmark, found the case exceptional under 35 U.S.C. 285 and awarded attorneys’ fees and costs to Highmark. The Federal Circuit affirmed the finding that Allcare’s allegations of infringement of claim 102 rendered the case exceptional, but reversed a finding that other claims and actions supported an exceptional case finding. Remand was necessary to determine the amount of fees apportionable to each of the issues. View "Highmark, Inc. v. Allcare Health Mgmt. Sys. Inc." on Justia Law

Whoever “invents or discovers and asexually re-produces any distinct and new variety of plant, including cultivated sports, mutants, hybrids, and newly found seedlings, other than a tuber propagated plant or a plant found in an uncultivated state, may obtain a patent therefor,” 35 U.S.C. 161. In 1980, Beineke noticed two white oak trees with superior genetic traits, such as excellent timber quality and strong central stem tendency. The trees were in the yard of another and about 105-118 years old. Beineke planted acorns from each. An examiner rejected patent applications because Beineke did not provide evidence that the trees were in a cultivated state. The Board affirmed, finding that the land on which the trees grew had existed as a wooded pasture until a house was constructed around 1930, after the trees began growing; there was no evidence that human activity contributed to the creation of the trees. The Federal Circuit affirmed, without addressing cultivation. Congress recognized that the relevant distinction was not between living and inanimate things, but between products of nature, whether living or not, and human-made inventions.” The trees were not “newly found seedlings,” and do not fall within the broadened protection of the 1954 amendments. View "In re Beineke" on Justia Law

Lovenox (enoxaparin) prevents blood clots. Enoxaparin is a version of heparin. Heparin molecules have considerable diversity in characteristics. Additional diversity is introduced when heparin is broken down, raising a problem with the FDA abbreviated new drug application (ANDA) process. ANDAs are used to obtain approval for a generic version of an existing drug and do not require extensive studies needed to initially prove the drug’s safety and efficacy. Aventis, which marketed Lovenox, asked the FDA to deny ANDA approval for a generic enoxaparin unless the applicant took certain steps. The FDA rejected Aventis’s arguments, stating that ANDA does not describe the information necessary to demonstrate that the active ingredient in the generic product is the same as the active ingredient in the reference drug. The FDA identified its own criteria for determining that generic enoxaparin has the same active ingredient as Lovenox. Amphastar was first to file an ANDA for generic enoxaparin and received FDA approval in2011. Momenta was first to bring generic enoxaparin to market, obtaining FDA approval more than a year earlier. Momenta alleged that Amphastar infringed its patent for analyzing heparin and obtained an injunction. The district court found that Amphastar’s quality control batch testing infringed the patent. The Federal Circuit vacated. The court applied an unduly narrow interpretation of the Hatch-Waxman safe harbor, 35 U.S.C. 271(e)(1).View "Momenta Pharma., Inc. v. Amphastar Pharma, Inc." on Justia Law

Defense contractor Raytheon, specializes in infrared imaging. Indigo, also specializing in infrared imaging, was founded by former Raytheon employees including Woolaway, who promised not to recruit Raytheon employees. Indigo began consulting for Raytheon, governed by Confidential Disclosure Agreements. In 1997, Raytheon became concerned that Indigo was recruiting Raytheon personnel to gain access to trade secrets. The companies settled the matter by agreement. The relationship between Raytheon and Indigo terminated in 2000. In 2000, Indigo won a military contract; in 2003, Indigo was selected over competitors, including Raytheon, to receive another subcontract. In 2004, Raytheon acquired and disassembled an Indigo infrared camera and found what it believed was evidence of patent infringement and trade secret misappropriation. In 2007, Raytheon found a correlation with the expertise of former employees who had departed for Indigo. The district court dismissed claims of trade secret misappropriation as time barred. The Federal Circuit reversed. The district court erred by resolving genuine factual disputes in favor of Indigo, the moving party, and concluding that Raytheon should have discovered its claims before March 2, 2004. View "Raytheon Co. v. Indigo Sys. Inc." on Justia Law

01 Communique is the owner of the 479 Patent, which relates to technology that enables one computer to access another computer remotely via the Internet. The patent contains five independent claims describing systems, methods, and products for enabling such remote access, as well as numerous claims dependent therefrom. It discloses use of a “locator server computer” as an intermediary between a “remote computer” (the computer seeking access) and a “personal computer” (the computer to be accessed). The locator server computer “includes” software, referred to in the patent as a “location facility,” that locates the personal computer. The district court entered summary judgment of noninfringement, based on construction of a single claim term, “location facility.” The Federal Circuit vacated, finding the claim construction erroneous. View "01 Communique Lab., Inc. v. Logmein, Inc." on Justia Law

Grober invented a platform that stabilizes a camera for filming motion pictures from moving vehicles. Known in the entertainment industry as the Perfect Horizon, the technology won Grober an Academy Award in technical achievement. He received a patent, entitled “Autonomous Self Leveling, Self Correcting Stabilized Platform.” for the invention, designed to compensate for motion caused by waves, currents, wind, and other motion during land, air, and sea operations of a camera. Grober claimed infringement. The district court entered summary judgment in favor of defendants. The Federal Circuit vacated the claim construction and the grant of summary judgment and remanded. A patent is infringed if even a single claim is infringed and the district court misconstrued term “payload platform.” View "Grober v. Mako Prods., Inc." on Justia Law

Antor owns the 961 patent relating “to a method and apparatus for transmitting information recorded on digital disks from a central server to subscribers via a high data rate telecommunications network.” The goal of the ’961 patent is to allow subscribers to access and to receive information (digital media such as music, images, documents, video, and software) stored on information systems over a telecommunications network. On reexamination the Patent and Trademark Office rejected the patent as anticipated and obvious over four references. The Federal Circuit affirmed. The Board correctly held that the existence of licenses under the patent is, alone, insufficient to overcome the prima facie case of obviousness View "In re: Antor Media Corp." on Justia Law

The two patents in suit relate to systems for minimizing the cost of placing long-distance telephone calls. Mediatrix manufactures and sells equipment that modifies existing telephone systems to convert them to voice-over-Internet-protocol systems. Over the course of infringement litigation, plaintiff (RTI) was ordered on four separate occasions to respond to a specific contention interrogatory propounded by Mediatrix: “Separately for each claim of the Patents-in-suit that [RTI] contends is infringed, state the basis for that contention, including without limitation, identification on an element-by-element basis of the component, structure, feature, functionality, method or process of each accused Mediatrix product that allegedly satisfies each element.” A magistrate determined that RTI never adequately responded to the interrogatory and that the failure to comply with the court’s orders was willful, and recommended dismissing the case and imposing monetary sanctions against RTI’s attorney, Hicks, and RTI in the amount of $86,965.81, to be split evenly between them. The district court adopted the recommendation. Hicks appealed the monetary sanction. RTI did not appeal. The Federal Circuit affirmed. View "Rates Tech., Inc. v. Mediatrix Telecom, Inc." on Justia Law